Clin Mol Hepatol.
2022 Oct;28(4):725-738. 10.3350/cmh.2022.0015.
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
- Affiliations
-
- 1Department of Gastroenterology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 2Department of Endocrinology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 3Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy
- 4Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Southampton, UK
- 5NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 6Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China
- KMID: 2534339
- DOI: http://doi.org/10.3350/cmh.2022.0015
Abstract
- Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease
- The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
- Should you advocate for hepatocellular carcinomasurveillance in patients with alcohol-related liverdisease or non-alcoholic fatty liver disease?
- As sociation of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome over 65 Years Elderly
- GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
